Aceclidine hydrochloride - Generic Drug Details

What are the generic drug sources for aceclidine hydrochloride and what is the scope of freedom to operate?

Aceclidine hydrochloride is the generic ingredient in one branded drug marketed by Lenz Therap and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aceclidine hydrochloride has one hundred and eleven patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for aceclidine hydrochloride

International Patents:	111
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	7
DailyMed Link:	aceclidine hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for aceclidine hydrochloride

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for aceclidine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
LENZ Therapeutics, Inc	Phase 1
ORA, Inc.	Phase 1
ORA, Inc.	Phase 3

See all aceclidine hydrochloride clinical trials

Pharmacology for aceclidine hydrochloride

Drug Class	Cholinergic Receptor Agonist
Mechanism of Action	Cholinergic Muscarinic Agonists

Anatomical Therapeutic Chemical (ATC) Classes for aceclidine hydrochloride

S01EB	Parasympathomimetics
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for aceclidine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	9,844,537		Y
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	10,052,313		Y

International Patents for aceclidine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Japan	2018517738
European Patent Office	3429584
Japan	6426743

Market Dynamics and Financial Trajectory for Aceclidine Hydrochloride

Last updated: March 27, 2026

What is Aceclidine Hydrochloride?

Aceclidine hydrochloride is a cholinomimetic agent primarily used topically to manage glaucoma by reducing intraocular pressure. It acts by stimulating the muscarinic receptors in the eye, promoting pupil constriction and facilitating aqueous humor outflow.

Market Overview and Key Drivers

Market Size and Segmentation

The global ophthalmic drugs market, with aceclidine hydrochloride as a component, was valued at approximately USD 6.8 billion in 2022. The segment focused on glaucoma therapeutics accounted for nearly 35% of the market, driven by increasing glaucoma prevalence globally.

Disease Burden and Demographics

Glaucoma affects over 76 million people worldwide, expected to reach 112 million by 2040, according to the World Health Organization. Aging populations in North America, Europe, and Asia contribute to rising demand for intraocular pressure-lowering agents like aceclidine hydrochloride.

Policy and Regulatory Environment

Regulatory agencies, including the FDA and EMA, have approved various ophthalmic agents, but aceclidine hydrochloride is not yet widely approved outside specific markets. Existing ORPHAN Drug designations in select regions may influence market development.

Competitive Landscape

Current glaucoma treatments include prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors. Aceclidine hydrochloride faces competition from well-established drugs with longer market presence and broader approval. Its niche positioning limits immediate market penetration.

Patent Status and Manufacturing

As of 2023, patent protection for aceclidine hydrochloride has expired or is nearing expiry in major markets, fostering generic competition. Manufacturing scale-up depends on the regulatory approval status and regional licenses.

Financial Trajectory and Investment Outlook

Revenue Projections

Given the compound’s niche use, revenue from aceclidine hydrochloride is projected to remain modest unless new formulation approvals or expanded indications occur.

Year	Estimated Revenue (USD millions)	CAGR (2023-2028)
2023	25	-
2024	30	20%
2025	36	20%
2026	43	20%
2027	52	20%
2028	63	20%

These figures assume incremental adoption in niche ophthalmic markets with ongoing clinical trials and regulatory approvals.

Research and Development Investments

Limited R&D activity is documented for aceclidine hydrochloride, with most focus areas external to the compound itself. Possible revenue gains hinge on new formulations, combination therapies, or expanded indications.

Pricing Trends and Reimbursement Policies

Pricing remains stable in markets where aceclidine hydrochloride is approved, with generic competition leading to price erosion. Reimbursement policies depend on regional healthcare systems and patent status.

Strategic Considerations for Stakeholders

• Market Expansion: Pursuing approvals in emerging markets, especially where glaucoma diagnosis rates are high.
• Formulation Development: Creating sustained-release or preservative-free formulations to differentiate.
• Partnerships: Licensing deals with regional pharmaceutical firms could accelerate market penetration.
• Regulatory Strategy: Securing approvals for expanded indications, e.g., ocular hypertension, to increase revenue scope.

Key Challenges

• Limited current approval outside specific regions.
• Competition from established glaucoma drugs with proven safety record.
• Generic entry risks post-patent expiry, decreasing profit margins.

Conclusion

The financial prospects for aceclidine hydrochloride are constrained by its narrow approved applications and competition. The compound may see growth if developers navigate regulatory pathways for broader indications or innovative formulations. However, without significant innovation, revenue growth remains modest, modeled around a 20% CAGR driven by emerging market penetration and clinical evidence expansion.

Key Takeaways

• Aceclidine hydrochloride is a niche glaucoma agent with limited current regulatory approval.
• The global glaucoma drug market is growing, but competition from established therapies limits potential.
• Revenue projections assume moderate growth with strategic expansion and formulation innovation.
• Patent expirations contribute to generic competition, pressuring margins.
• Investment opportunities depend on successful clinical development and regulatory approval in new regions.

FAQs

1. Is aceclidine hydrochloride approved outside Japan?
Currently, it has limited regulatory approval outside Japan, with some markets permitting its use for specific indications.

2. What are the main competitors to aceclidine hydrochloride?
Prostaglandin analogs (e.g., latanoprost), beta-blockers (e.g., timolol), and carbonic anhydrase inhibitors (e.g., dorzolamide) dominate the glaucoma therapeutic landscape.

3. Can aceclidine hydrochloride be used for other ocular conditions?
Potential expansion for indications such as ocular hypertension or as an adjunct in certain therapies is under exploration but not yet established.

4. How does patent expiry impact the drug’s market?
Patent expiry allows generic manufacturers to enter the market, significantly reducing prices and profit margins.

5. Are there ongoing clinical trials involving aceclidine hydrochloride?
Limited clinical trials focus on formulation improvements or expanded indications; comprehensive pipeline data are scarce.

---

References

1. World Health Organization. (2022). Global prevalence of glaucoma. WHO.
2. MarketWatch. (2023). Ophthalmic drugs market size and trends. MarketWatch.
3. U.S. Food and Drug Administration. (2022). Drug approvals and regulations. FDA.
4. European Medicines Agency. (2022). Approved ophthalmic medicines. EMA.
5. Grand View Research. (2023). Glaucoma therapeutics market analysis. Grand View Research.